Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,030.80
(
-1.08%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
109.74
(
1.49%
)
Bitcoin
68,496.75
(
0.97%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: jq1234 post# 176702

Saturday, 04/12/2014 2:29:39 AM

Saturday, April 12, 2014 2:29:39 AM

Post# of 257269
ABBV/ENTA TURQUOISE-II cirrhotic patients 12-week: Overall SVR12=92% for 3-DAA plus RBV. For trt naive, SVR12=94%; for trt experienced, SVR12=90%.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402869

[Generally speaking similar to ION-1, 2 cirrhotic patients taking consideration ION-2 included some Incivek/Victrelis treated.]

SAPPHIRE-I: trt naive.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1315722

SAPPHIRE-II: trt experienced.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401561

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today